Rupee V/s Dollar, March 11, 2025: Rupee rises 1 paisa to ₹87.30

Early market activity on Tuesday March 11, 2025 resulted in a 1 paisa rise of the Indian rupee to ₹87.30 against the US dollar. The Indian currency dropped 36 paise on Monday until it reached ₹87.31 against the US dollar. The early market rise on Tuesday came as a result of both the weak US dollar and declining crude oil prices. The interbank foreign exchange started the day with a rupee value of ₹87.37 before it fell slightly to ₹87.39 and rose again to ₹87.30 against the dollar.

Factors Impacting Investor Sentiment

The rupee experienced an early increase but domestic equity market volatility combined with concerns about an American recession along with trading uncertainties created a negative investor sentiment. Forex traders noted these factors. The Indian stock market indexes declined on Tuesday as both the 30-share BSE Sensex dropped 424.36 points (0.57%) to 73,690.81 points while the Nifty dropped 117.90 points (0.52%) to reach 22,342.40 points.

Global Economic Influences

The dollar index exhibiting a decrease of 0.20 percent reached a value of 103.75 during trading. Brent crude, the international standard for measuring oil prices, recorded a 0.01 percent increase to reach USD 69.29 per barrel in future exchange transactions.

US-China Trade Tensions and Recession Concerns

During his international address President Donald Trump dismissed the business fears stemming from his trade tax measures but failed to eliminate the risk of market recession because of rising prices. The additional Chinese 15 percent duty against US farm products including chicken, pork, soybeans, and beef came after Trump imposed his 20 percent Chinese import tariff. The rising trade conflicts between the countries triggered a sudden market downturn on US trading days.

Other Relevant Economic Indicators

On Monday it was reported by exchange data that foreign institutional investors (FIIs) sold Indian equities totaling ₹485.41 crore on a net basis.

Disclaimer: This is not a recommendation to buy or sell a stock. 

To read the RA disclaimer, please click here